Search

Displaying results 251 - 260 of 337 in total
  1. Drug

    Temozolomide

    go.drugbank.com/drugs/DB00853
    ApprovedInvestigational

    It is currently marketed under the trademark TEMODAR® by Merck.[L32033]

  2. Drug

    Pyrithione

    go.drugbank.com/drugs/DB06815
    ApprovedInvestigational

    Pyrithione zinc, or zinc pyrithione or zinc pyridinethione, is a coordination complex consisted of pyrithione ligands chelated to zinc (2+) ions via oxygen and sulfur centers. In the crystalline state, it exists as a centrosymmetric dime...

    Products: Members Mark Gentle Dandruff
  3. Drug

    Mumps virus strain B level jeryl lynn live antigen

    go.drugbank.com/drugs/DB10316
    ApprovedInvestigational

    Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.

    Mixtures: PROQUAD® ( Measles, Mumps, Rubella AND Varicella (Oka/Merck) Virus Vaccine Live, MSD) LYOPHILIZED VACCINE;
  4. Drug

    MK-0354

    go.drugbank.com/drugs/DB05939
    Investigational

    MK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.

  5. Drug

    Myrcludex B

    go.drugbank.com/drugs/DB14853
    Investigational

    Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination

  6. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    This approval was supported by positive results in multiple trials, including the KINECT-HD Phase 3 study and the ongoing KINECT-HD2 open-label extension trial.

  7. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  8. Drug

    BMN-351

    go.drugbank.com/drugs/DB18186
    Investigational

    BMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA.

  9. Drug

    Atrazine

    go.drugbank.com/drugs/DB07392
    Experimental

    (From The Merck Index, 11th ed)

  10. Drug

    Mavorixafor

    go.drugbank.com/drugs/DB05501
    ApprovedInvestigational

    Mavorixafor is a CXC chemokine receptor 4 (CXCR4) antagonist. It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficienc...